Replies to post #104874 on Biotech Values

[pollyvonwog]

It's simple - there is little demand for shares.

Correct. I expect quarter numbers to change that.

On your other points, only one sell-side analyst has said that they expect TEVA approval by end of year. All the rest say TEVA is at least a year if not longer or ever from approval. Oppenheimer bought 5 million shares a few weeks back, so looks like one of the "big boys" thinks its worth something....

[10nisman]

If fund managers thought they could make money and MNTA were cheap - they would be buyers. If there's $$$ to be made rest assured they will.

That's why the vast majority (70+%) of all fund managers don't beat their benchmark. They sell when they should be buying and buying when they should be selling.

10nis